Sustainable products and supply chains

Towards a circular economy—an introduction

The two main aims behind the concept of a circular economy are minimising the generation of waste and maintaining the value of products and materials within the economy for as long as possible.

On 2 December 2015, the Commission adopted a Circular Economy Package to stimulate Europe's transition towards a circular economy. The package entailed a series of revisions to existing waste directives (including the Waste Framework and Packaging Waste Directives) made in 2018, together with supporting measures and guidance produced by the Commission.

On 11 March 2020, as part of the European Green Deal, the Commission adopted a new Circular Economy Action Plan (2020 CEAP). The 2020 CEAP adjusted the primary focus of circular economy policy away from waste management and onto the entire life cycle of products. The plan targets how products are designed, promotes circular economy processes, encourages sustainable consumption, and aims to ensure that waste is prevented in the first instance and that resources are kept in the EU economy for as long as possible.

In follow up to the 2020 CEAP, the Commission

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

TAKE A FREE TRIAL

Latest EU Law News

EMA launches AI research priorities survey to inform regulatory focus

The European Medicines Agency (EMA) has launched an EU survey ran by the joint HMA-EMA Network Data Steering Group (NDSG) to identify key research priorities for artificial intelligence (AI) in the development and evaluation of medicines. It aims to gather structured input from stakeholders including the European Medicines Regulatory Network (EMRN), industry, SMEs, patients, consumers, academics and healthcare professionals. Survey feedback will be used to define priority areas that can support safe and effective use of AI in medicine, with the findings to be shared with the broader research community to advance academic and multi-stakeholder research. The survey forms part of the NDSG’s 2025–2028 workplan to optimise data use and leverage AI for better decision-making in medicines regulation. The survey closes on 17 October 2024.

Do not bottle the truth—major soft drinks company commits to correcting its recycling claims under EU law

EU Law analysis: Gabriela de Costa, Georgina Rigg, Aurelija Grubytė and Anna Carter of K&L Gates consider the following-In November 2023, a coalition of consumer protection organisations from across the EU reported several major bottled drinks companies to the European Commission and the Consumer Protection Authorities (CPA Network) for making misleading recycling claims on their bottles. Following the complaint, a global drinks company voluntarily offered to make a series of changes to the recycling claims on its plastic bottles

EMA publishes EU network data strategy following public consultation

The European Medicines Agency (EMA) has published the European Medicines Agencies Network Data Strategy on 3 October 2025, following a public consultation conducted between November and December 2024. The strategy focuses on making more effective use of data hosted by the European medicines regulatory network and aims to ensure data meets high quality standards whilst being appropriately organised, standardised and easily shared among regulators and stakeholders. The document, reference number EMA/128369/2025, is intended to facilitate collaboration and more informed regulatory decision-making across the network. The strategy builds on EMA's existing work in leveraging data including regulatory submissions data, substance and product master data, and real-world data such as electronic health records and patient registry data to support public health decisions in the European Union.

EFPIA blog calls for refinement of EU GLP proposals

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has published a blog welcoming the revision of the EU’s General Pharmaceutical Legislation (GPL), while cautioning that some provisions—such as limited flexibility in using Real-World Evidence and the exclusion of marketing authorisation holders from labelling decisions when data is generated by regulators or third parties—could unintentionally undermine the framework’s effectiveness if not refined.